Covid19 Clinical Trial
— PIANO-COVID-19Official title:
Effect of Organizational Measures to Prevent and Control COVID-19 Infection in Nursing Homes on the Risk of Death of Residents During and After the Epidemic Period
| NCT number | NCT04740658 |
| Other study ID # | RC31/20/0300 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | July 8, 2021 |
| Est. completion date | March 31, 2022 |
| Verified date | March 2023 |
| Source | University Hospital, Toulouse |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The COVID epidemic has shown very high mortality among older people, especially among poly-morbid and dependent subjects. In addition to the classic risk factors of age, dependence and associated co-morbidities, community life exposes to specific increased risks in the event of this easily inter human transmissible viral epidemic. In France, according to the Direction of research, studies, evaluation and statistics (DREES) data (Ehpa study, 2015) more than 600,000 elderly people currently live in nursing homes (NH). Since March 28, a national guidance for monitoring the COVID epidemic in NH has just been set up. In France, 14 178 of the 29 319 COVID deaths (48.35%) by June 10th 2020 occurred among NHs residents. Work to consolidate these data is underway, suggesting a much heavier balance sheet. Faced to this threat, in addition to practical recommendations (barrier protection gestures), strict instructions were also announced to all NH to keep their residents safe from COVID : restricting all visitors, all volunteers and nonessential personnel, and more recently, confining residents in their room in case of incident case of COVID in the NH. Organizational factors of NH such as the prevention strategies deployed before and during the epidemic (pneumococcal vaccination, restricting group activities), as well as NH internal resources (equipment, nursing staff) and health resources in the NH environment (hospital partnerships, support devices, telemedicine) lead to heterogeneous situations and could influence the death rates of residents. On the other hand, social isolation can also precipitate the decline of fragile residents. Beyond the immediate and directly risks linked to COVID-19, the present hypothesize that the organizational measures (guidance and recommendations) put in place can have, during and at a distance from the outbreak, beneficial effects but also deleterious effects depending on the severity of the outbreak of a geographic area. More precisely, the hypothesis is that strong and well-followed recommendations at the time of the epidemic were associated with a reduction in the risk of total death in particular of deaths related to COVID in the zones most affected by the epidemic but also that strong and well-followed recommendations were associated with an increased risk of total death, in particular of deaths unrelated to COVID in the areas least affected by the epidemic.
| Status | Completed |
| Enrollment | 12166 |
| Est. completion date | March 31, 2022 |
| Est. primary completion date | March 31, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Within each NH, all NH residents living in the NH the 1st of January 2020 will be included. Exclusion Criteria: - NHs or Long Term Care Facilities (LTCFs) that refuse to participate. - NHs that are not voluntary or not located in the regions and NHs that do not have a coordinating doctor . - Within each NH, all NH residents not living in the NH or LTCFs the 1st of January 2020 will be not be included. |
| Country | Name | City | State |
|---|---|---|---|
| France | University Hospital Toulouse - Gérontopôle | Toulouse |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Toulouse |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | deaths not related to COVID during the one-year follow-up | The secondary objective N°2 is to compare the rate of death not related to COVID cases in NH with a high level of implementation of the recommendation/guidance to prevent and control COVID-19 NH residents' infection and NH with a low level of implementation of the recommendation/guidance to prevent and control COVID-19 NH. | from January 2020 to December 2020 | |
| Other | evaluate the economic impact of the implementation of prevention measures | This secondary objective N°3 is to evaluate the economic impact of the implementation of prevention measures applied by nursing homes staff, from healthcare system and the NH perspectives.
- Direct medical and non-medical costs 6 and 12 months before and after the high or low level implementation of recommendations to prevent and control COVID-19, using the Mandatory National Health Insurance database. |
6 and 12 months before and after the implementation of the preventive measures | |
| Other | Health economic study: evaluate Direct medical and non-medical costs | This secondary objective N°3 is to evaluate the economic impact of the implementation of prevention measures applied by nursing homes staff, from healthcare system and the NH perspectives.
- Direct medical and non-medical costs rate to assess the cost-effectiveness of high-level implementation of recommendation to prevent and control COVID-19. |
6 and 12 months before and after the implementation of the preventive measures | |
| Other | Health economic study: evaluate the mortality rate | This secondary objective N°3 is to evaluate the economic impact of the implementation of prevention measures applied by nursing homes staff, from healthcare system and the NH perspectives.
- Mortality rate to assess the cost-effectiveness of high-level implementation of recommendation to prevent and control COVID-19. |
6 and 12 months before and after the implementation of the preventive measures | |
| Primary | Death occurrence within one year of follow up | Primary criteria is death occurrence within one year of follow up: death rates will be recorded.
Level of implementation of the recommendation/guidance to prevent and control COVID-19 NH residents' infection will be score 14 days before the peak wave of the outbreak in the geographic area of each NH. |
from January 2020 to December 2020 | |
| Secondary | deaths related to COVID during the one-year follow-up | The secondary objective N°1 is to compare the rate of death related to confirmed or suspected COVID cases in NH with a high level of implementation of the recommendation/guidance to prevent and control COVID-19 NH residents' infection and NH with a low level of implementation of the recommendation/guidance to prevent and control COVID-19 NH. | from January 2020 to December 2020 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |